Physician profile
Renee Nelson
NPI 1821190224
$7,452.44
in general payments reported to CMS, 2019-2025
37 companies · $1,605 in 2025
The $1,605 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,106 · 2020: $751 · 2021: $746 · 2022: $1,138 · 2023: $474 · 2024: $1,633 · 2025: $1,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,510 · Education: $200 · Travel and Lodging: $2.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,510.04 |
| Education | $199.98 |
| Travel and Lodging | $2.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,480.01 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $1,066.60 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Genzyme Corporation | $810.54 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $663.65 | 2019-2024 | Ofev |
| Insmed, INC. | $601.01 | 2022-2025 | Arikayce, Brinsupri |
| Jazz Pharmaceuticals INC. | $571.97 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $376.31 | 2019-2025 | Opsumit, Uptravi |
| Philips North America LLC | $169.89 | 2019-2025 | (8874) Incourage, Encore |
| Advanced Respiratory, INC | $159.10 | 2020-2021 | |
| Hill-Rom Company, INC | $150.00 | 2021 | |
| Mylan Specialty L.P. | $143.00 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $142.12 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.29 | 2021-2023 | Glassia |
| Pfizer INC. | $121.14 | 2020-2022 | |
| Allergan, INC. | $112.03 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $100.54 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Abbvie INC. | $91.22 | 2024-2025 | |
| Verona Pharma, INC. | $59.17 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $50.58 | 2021 | |
| Gilead Sciences, INC. | $47.45 | 2019-2021 | |
| Hospira, INC. | $44.03 | 2022 | |
| Genentech USA, INC. | $43.67 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $33.87 | 2019 | |
| Alnylam Pharmaceuticals INC. | $32.27 | 2022 | |
| Merck Sharp & Dohme LLC | $30.72 | 2024 | Winrevair |
| Biohaven Pharmaceutical Holding Company Ltd. | $30.05 | 2022 | |
| Circassia INC. | $25.68 | 2019 | |
| Harmony Biosciences LLC | $23.38 | 2022 | |
| Grifols USA, LLC | $19.85 | 2019 | |
| Vyera Pharmaceuticals, LLC | $18.74 | 2020 | |
| United Therapeutics Corporation | $17.31 | 2023 | Tyvaso |
| Teva Pharmaceuticals USA, INC. | $16.96 | 2021 | |
| Paratek Pharmaceuticals, INC. | $16.54 | 2021 | |
| Avion Pharmaceuticals | $15.33 | 2019 | |
| Amgen INC. | $14.96 | 2020 | |
| Resmed Corp | $14.46 | 2019 | |
| Shionogi INC | $14.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.